Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Disruptive Pharma ABOSTO:DPHA +0.83%4 EBITDA Margin % is % as of Jun. 2026. GuruFocus rates OSTO:DPHA with a GF Score™ of 4/100. Among 961 Drug Manufacturers companies, Disruptive Pharma AB ranks worse than 97.71% on this metric.
Disruptive Pharma AB (OSTO:DPHA) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Disruptive Pharma AB EBITDA Margin % Related Terms
Disruptive Pharma AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Disruptive Pharma AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Disruptive Pharma AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Disruptive Pharma AB EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Disruptive Pharma AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Disruptive Pharma AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Disruptive Pharma AB (OSTO:DPHA) has a EBITDA Margin % of % as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Disruptive Pharma AB and its competitors. According to the industry distribution chart, Disruptive Pharma AB ranks #939 out of 961 companies in the Drug Manufacturers industry, placing it in the top 97.7%.
Is Disruptive Pharma AB's EBITDA Margin % too high?
Disruptive Pharma AB's current EBITDA Margin % is %. Based on the distribution chart, Disruptive Pharma AB ranks #939 out of 961 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Disruptive Pharma AB has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Disruptive Pharma AB's EBITDA Margin % compare to ?
According to the Drug Manufacturers industry distribution chart, Disruptive Pharma AB ranks #939 out of 961 companies for EBITDA Margin %. This places Disruptive Pharma AB in the lower half of its industry. The industry median EBITDA Margin % is 11.88. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 11.88, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Disruptive Pharma AB and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 11.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Disruptive Pharma AB's current EBITDA Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Disruptive Pharma AB stock overvalued right now?
Disruptive Pharma AB (OSTO:DPHA) has a current EBITDA Margin % of %. The current EBITDA Margin % is %. Disruptive Pharma AB's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Disruptive Pharma AB (OSTO:DPHA), the current EBITDA Margin % is % as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Disruptive Pharma AB is a Swedish drug delivery technology company developing and commercializing Formulite, a patented platform based on mesoporous magnesium carbonate (MMC). The platform is designed to improve the solubility, oral bioavailability and other properties of pharmaceutical compounds. The company's business model is based on contract development, partnerships and licensing arrangements with pharmaceutical and biotechnology companies for the development and commercialization of drug products optimized with Formulite.
4GF Score
Get the complete analysis for OSTO:DPHA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:DPHA has been successfully added to your 
